CD3E and type 1 diabetes mellitus: Studies demonstrated that alternative T-cell-targeted therapies targeting CD3ɛ could alter the course of T1DM through downregulating of CD3ε/TCR signal and inhibiting the proliferation of T lymphocytes [45].